BioMarin
A quarter of billion-euro licences, a Novo comeback and a flat Nordic index – the State of Nordic BioPharma | 2026:Q3
Analytics
AstraZeneca strikes again, BioArctic’s Leqembi goes global and Cinclus holds its breath – the Nordic Pulse | 2026:36
